Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SC-006 + ABBV-181
- Development stage
- Discontinued
- Lead developer
- AbbVie
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SC-006 + ABBV-181 is a combination therapy consisting of **SC-006**, an antibody-drug conjugate (ADC) targeting DNA and **ring finger protein 43 (RNF43)**, and **ABBV-181** (also known as budigalimab), a humanized recombinant IgG1 monoclonal antibody that inhibits **programmed cell death protein 1 (PD-1)**. SC-006 acts as a DNA inhibitor and RNF43 inhibitor, while ABBV-181 (budigalimab) blocks immune checkpoint PD-1 to enhance antitumor immune responses. This combination was developed for treatment of advanced colorectal cancer and was investigated in a Phase 1 clinical trial as both monotherapy and combination therapy. Development in this indication was discontinued after thrombocytopenia limited dose escalation below predicted efficacy[1][2][3][4][5][6].
- Brand names
- budigalimab
- Other names
- SC-006SC006SC 006ABBV-181ABBV181ABBV 181budigalimab
02
Targets
DNARNF43 (Ring finger protein 43)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on SC-006 + ABBV-181.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SC-006 + ABBV-181.